[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
About Journal::
Editorial Board::
Articles Archive::
Indexing Databases::
To Authors::
To Reviewers::
Submit Your Article::
Policies and Publication Ethics::
Archiving Policy::
Site Facilities::
Contact Us::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 9, Issue 3 (6-2022) ::
2022, 9(3): 9-15 Back to browse issues page
Mebeverine alleviates lower urinary tract symptoms in patients with irritable bowel syndrome
Mansour Masoumi , Mastoreh Rahimi , Masoud Mami , Maryam Bagheri , Sajjad Salari
Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran , sajjad.salari@medilam.ac.ir
Abstract:   (1374 Views)
Introduction: Lower urinary tract symptoms (LUTS) are common in patients suffering from irritable bowel syndrome (IBS). LUTS are categorized into storage, voiding and post-micturition symptoms. Mebeverine, a voltage-gated sodium channel blocker, can alleviate IBS symptoms via inducing smooth muscle relaxation. The effect of mebeverine on LUTS is not cleared yet. Consequently, we aimed to evaluate the effect of mebeverine on LUTS in IBS patients.
Materials and Methods: Seventy-five IBS patients were included in the present study. IBS was diagnosed according to the Rome IV criteria. International prostate symptom score (I-PSS) questionnaire was used to evaluate LUTS and quality of life in IBS patient. Patients were treated with 200 mg mebeverine per day. All patients were assessed once before the treatment and then one, three and six months after the treatment with mebeverine.
Results: The prevalence and severity of voiding symptoms were significantly higher in males than females (P < 0.05). One-month treatment with mebeverine reduced storage and voiding urinary symptoms in IBS patients (P < 0.01 and P < 0.0001, respectively). The beneficial effects of mebeverine increased over the time and the maximum effect were found following six-months treatment (P < 0.0001). Furthermore, using mebeverine in IBS patients improved the quality of life both in men and women (P < 0.0001).
Conclusion: Mebeverine could obviously ameliorate both gastrointestinal and urinary symptoms in IBS patients. These findings may propose that smooth muscle relaxants including mebeverine might be proper therapeutic agents for IBS patients with LUTS.
Keywords: Irritable bowel syndrome, Lower Urinary Tract Symptoms, Mebeverine, Smooth muscle
Full-Text [PDF 375 kb]   (1861 Downloads)    
Type of Study: Research | Subject: Urology
Received: 2021/05/18 | Accepted: 2021/10/4 | Published: 2022/06/19
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Masoumi M, Rahimi M, Mami M, Bagheri M, Salari S. Mebeverine alleviates lower urinary tract symptoms in patients with irritable bowel syndrome. Journal of Basic Research in Medical Sciences 2022; 9 (3) :9-15
URL: http://jbrms.medilam.ac.ir/article-1-606-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 9, Issue 3 (6-2022) Back to browse issues page
مجله ی تحقیقات پایه در علوم پزشکی Journal of Basic Research in Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4654